Elanco Animal Health Incorporated (ELAN)
$
23.27
-0.04 (-0.17%)
Key metrics
Financial statements
Free cash flow per share
0.7287
Market cap
11.6 Billion
Price to sales ratio
2.5184
Debt to equity
0.5962
Current ratio
2.4007
Income quality
17.4722
Average inventory
1.7 Billion
ROE
0.0055
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Elanco Animal Health Incorporated is an established player in the animal health sector, innovating and developing a diverse array of products designed for both pets and farm animals. The company reported an income before tax of 488,000,000.00 showcasing its pre-tax profitability. The cost of revenue for the company is $2,530,000,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $4,188,000,000.00 reflecting its overall spending. Additionally, Elanco reported selling, general, and administrative expenses of $1,314,000,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 497,300,000.00 reflecting potential dilution effects. Elanco focuses on pet health with disease prevention products such as parasiticides and vaccines protecting pets from common parasites like worms, fleas, and ticks under renowned brands including Seresto, Advantage, Advantix, and Advocate. It also offers therapeutics for various conditions in canines and felines under the Galliprant and Claro brands. Moreover, the company provides vaccines, antibiotics, and nutritional health products for poultry and aquaculture, alongside essential products for ruminant and swine production under the Rumensin and Baytril brands. Elanco serves a broad customer base, including third-party distributors, veterinarians, and farm animal producers ranging from beef and dairy farmers to those in the pork and poultry sectors. As an organization, Elanco Animal Health operates within the Healthcare sector, driving innovation and growth within the industry. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Investors seeking budget-friendly options may find the stock affordable at $19.20 making it suitable for those who are budget-conscious. Additionally, the stock has a high average trading volume of 5,518,395.00 indicating strong liquidity in the market. With a mid-range market capitalization of $11,562,013,017.00 the company is recognized as a steady performer, showcasing its reliability and consistent contributions to the animal health field.
Is Elanco Animal Health Incorporated (ELAN) a good investment?
Investing in Elanco Animal Health Incorporated (ELAN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Elanco Animal Health Incorporated (ELAN)'s stock forecast?
Analysts predict Elanco Animal Health Incorporated stock to fluctuate between $8.02 (low) and $23.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Elanco Animal Health Incorporated's market capitalization?
As of 2025-11-28, Elanco Animal Health Incorporated's market cap is $11,562,013,017, based on 496,863,473 outstanding shares.
How does Elanco Animal Health Incorporated compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Elanco Animal Health Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Elanco Animal Health Incorporated (ELAN) stock?
To buy Elanco Animal Health Incorporated (ELAN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELAN. Place an order (Market, Limit, etc.).
What is the best time to invest in Elanco Animal Health Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Elanco Animal Health Incorporated perform in the last earnings report?
Revenue: $4,439,000,000 | EPS: $0.68 | Growth: -127.20%.
Where can I find Elanco Animal Health Incorporated's investor relations reports?
Visit https://www.elanco.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Elanco Animal Health Incorporated?
You can explore historical data from here
What is the all-time high and low for Elanco Animal Health Incorporated stock?
All-time high: $36.50 (2021-08-05) | All-time low: $7.88 (2023-05-31).
What are the key trends affecting Elanco Animal Health Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
/PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ and NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to
prnewswire.com
MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.
benzinga.com
As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.
youtube.com
Jeff Simmons, Elanco Animal Health CEO, joins 'The Exchange' to discuss what's driving the company's earnings results, where the company's is devoting the most resources and much more.
seekingalpha.com
Elanco Animal Health Incorporated ( ELAN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tiffany Kanaga Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Linda Bolduc - Morgan Stanley, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Navann Ty Dietschi - BNP Paribas, Research Division Andrew Dusing - Cleveland Research Company LLC Presentation Operator Ladies and gentlemen, thank you for standing by.
zacks.com
The headline numbers for Elanco Animal Health (ELAN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.13 per share a year ago.
prnewswire.com
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% organic constant currency growth Reported Net Loss of $34 million, Adjusted Net Income of $94 million Adjusted EBITDA of $198 million; Adjusted EBITDA Margin of 17.5% Reported EPS of $(0.07), Adjusted EPS of $0.19 Net leverage ratio of 3.7x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,645 million to $4,670 million; expect accelerating organic constant currency revenue growth of 6% to 6.5% vs. 3% in 2024 Raising 2025 innovation revenue target by $100 million at the midpoint of the range to $840 to $880 million Reported Net Loss of $56 million to $41 million, raising guidance for Adjusted EBITDA to $880 million to $900 million Reported Loss Per Share of $0.11 to $0.08, raising guidance for Adjusted EPS to $0.91 to $0.94 2025 year-end net leverage ratio target improved to 3.7x to 3.8x, enabled by year-to-date execution and disciplined working capital management INDIANAPOLIS , Nov. 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2025, provided guidance for the fourth quarter of 2025, and updated guidance for the full year 2025.
zacks.com
Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
prnewswire.com
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far this year,ii surpassing the total number of annual cases seen in all of 2019.iii Elanco continues to go beyond for veterinarians and pet owners, providing even more comprehensive protection against some of the most concerning ticks. INDIANAPOLIS, Ind.
See all news
